In April 2020, the Food and Drug Administration (FDA)

Trusted Source

requested that all forms of prescription and over-the-counter (OTC) ranitidine

(Zantac) be removed from the U.S. market. This recommendation was made
because unacceptable levels of NDMA, a probable carcinogen
(cancer-causing chemical), were found in some ranitidine products. If you’re
prescribed ranitidine, talk with your doctor about safe alternative options
before stopping the drug. If you’re taking OTC ranitidine, stop taking the drug
and talk with your healthcare provider about alternative options. Instead of
taking unused ranitidine products to a drug take-back site, dispose of them
according to the product’s instructions or by following the FDA’s guidance

Trusted Source

Ranitidine, brand name Zantac, is now marketed as Zantac 360, which

contains a different active ingredient (famotidine). Famotidine is in the same
class as ranitidine and works the same way but has not been found to contain
unacceptable levels of NDMA.